India to Bahrain: Arishta Export Trade Route

To import Arishta formulations into Bahrain, the following approvals and registrations are necessary:

1. Product Registration: All pharmaceutical products must be registered with the NHRA. The registration process involves submitting a comprehensive dossier that includes data on the product's quality, safety, and efficacy. The dossier should be formatted according to the Common Technical Document (CTD) or electronic CTD (eCTD) guidelines.

2. Gulf Central Committee for Drug Registration (GCC-DR) Approval: Products should be registered with the GCC-DR or recognized regulatory authorities such as the Saudi Food and Drug Authority (SFDA), the U.S. Food and Drug Administration (FDA), Health Canada, the European Medicines Agency (EMA), Swissmedic, the Therapeutic Goods Administration (TGA), the Japanese Ministry of Health, or the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

3. Importation Licensing: Importation of medicines is governed by Bahrain's Pharmacy Decree-Law No. 18 of 1997, amended by Decree-Law No. 20 of 2015, which states that the importation/exportation of medicines must be through an authorized legal entity. (nhra.bh)

4. Good Manufacturing Practice (GMP) Compliance: Manufacturing facilities must comply with GMP standards. The NHRA requires a valid GMP certificate, legalized and with a validity of at least three months, as part of the registration process. (bahrain.bh)

5. Timelines and Fees: The registration process timeline can vary, and specific fees are determined by the NHRA. It is advisable to consult the NHRA directly for the most current information on processing times and associated costs.

Indian exporters of Arishta formulations must adhere to the following quality and GMP standards to supply products to Bahrain:

1. WHO-GMP Certification: Manufacturers should hold a WHO-GMP certificate, ensuring that products are consistently produced and controlled according to quality standards.

2. NHRA Approval: The NHRA requires a valid GMP certificate, legalized and with a validity of at least three months, as part of the registration process. (bahrain.bh)

3. Facility Inspections: While specific details on recent inspections or regulatory actions by the GHC against Indian pharmaceutical companies are not publicly disclosed, compliance with GMP standards is mandatory. Manufacturers should ensure their facilities are prepared for potential inspections by Bahraini authorities.

In the past 18 months, several regulatory changes have impacted Indian pharmaceutical exports to Bahrain:

1. Revised GMP Regulations in India: On January 6, 2024, India's Ministry of Health published revised regulations in accordance with Annex M of the Drugs and Cosmetics Rules. These revisions aim to align India's GMP standards with global benchmarks, introducing elements such as a pharmaceutical quality system (PQS), quality risk management (QRM), product quality review (PQR), and validation of equipment.

2. NHRA's Implementation of GCC Unified Pricing: The NHRA is implementing the Gulf Health Council's unified pricing in consecutive waves. Local agents are notified of new prices and their implementation dates. Appeals regarding unified product prices are to be submitted directly to the Gulf Health Council. (nhra.bh)

These developments underscore the importance for Indian exporters to stay informed about regulatory changes both domestically and in the GCC region to ensure compliance and maintain market access.

Arishta formulations, rooted in the Ayurvedic system, are a subset of Bahrain's broader pharmaceutical market. In 2025, the overall pharmaceutical market in Bahrain is projected to reach approximately USD 168.10 million. Within this, the over-the-counter (OTC) pharmaceuticals segment, which includes herbal and Ayurvedic products, is expected to generate revenues of around USD 128.11 million.

The demand for Arishta formulations is influenced by several factors:

• Chronic Disease Prevalence: The rising incidence of chronic conditions such as diabetes and cardiovascular diseases has led to increased interest in alternative and complementary therapies, including Ayurvedic medicines.

• Healthcare Investment: Bahrain's commitment to enhancing its healthcare infrastructure and services has expanded access to various treatment modalities, including traditional and herbal medicines.

• Cultural Acceptance: A segment of Bahrain's population, familiar with traditional medicine systems, contributes to the sustained demand for products like Arishta formulations.

While Bahrain imports a significant portion of its pharmaceutical products, including Arishta formulations, there is limited domestic manufacturing capacity for such specialized herbal medicines. This reliance on imports underscores the importance of international trade partnerships in meeting the country's healthcare needs.

Bahrain maintains a 0% import duty rate for pharmaceutical products classified under HS code 30049011, which encompasses Ayurvedic formulations like Arishta. This exemption aligns with Bahrain's policy to ensure the affordability and availability of essential medicines.

Additionally, Bahrain has established Free Trade Agreements (FTAs) with several countries, including India. These agreements further facilitate the seamless importation of pharmaceutical products by eliminating or reducing trade barriers. There are no reported anti-dumping duties or additional charges specifically targeting pharmaceutical imports under this HS code.

India is the primary supplier of Arishta formulations to Bahrain, accounting for approximately 62.15% of the imports under HS code 30049011. (eximpedia.app) Other notable suppliers include Germany, Singapore, Sri Lanka, and Spain.

India's dominance in this segment is attributed to its extensive production of Ayurvedic medicines and cost-effective manufacturing processes. The average import price for Ayurvedic products like Tentex Royal Capsules from India to Bahrain has been around USD 2.43 per unit. In comparison, European manufacturers often have higher production costs, leading to higher pricing for similar products.

The competitive pricing and established trade relations between India and Bahrain position Indian manufacturers favorably in the Bahraini market for Arishta formulations.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. The country's pharmaceutical industry is supported by over 10,800 manufacturing facilities, including more than 3,500 WHO-GMP approved plants and 750 USFDA-compliant facilities, representing the largest concentration of regulatory-approved pharmaceutical facilities outside the United States.

The cost structure of Indian pharmaceutical manufacturing is highly competitive, with production costs estimated to be 30-40% lower than those in Western countries. This cost efficiency is achieved through economies of scale, a skilled workforce, and a well-established supply chain. Additionally, India's pharmaceutical sector has seen significant investments in infrastructure that meets global regulatory standards, enhancing its capacity to produce high-quality finished dosage forms, including tablets, capsules, and syrups.

When comparing Arishta formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian pharmaceutical products are generally more cost-effective than those from the EU, with production costs estimated to be 30-40% lower than in Western countries. While specific pricing data for Arishta formulations is not readily available, India's overall cost advantage is well-documented.

• Quality Perception: India's pharmaceutical industry is recognized for its adherence to international quality standards, with over 3,500 WHO-GMP approved plants and 750 USFDA-compliant facilities. This extensive regulatory compliance underscores the high quality of Indian pharmaceutical products.

• Regulatory Acceptance in Bahrain: Bahrain's regulatory framework is aligned with international standards, and Indian pharmaceutical products are well-accepted in the Bahraini market. The presence of WHO-GMP and USFDA approvals facilitates smoother regulatory approvals in Bahrain.

• Supply Reliability Track Record: Indian pharmaceutical companies have a strong track record of supply reliability, supported by a robust manufacturing infrastructure and a well-established supply chain. The industry's commitment to maintaining high-quality standards and meeting international regulatory requirements further enhances its reliability as a supplier.

The India-Bahrain supply chain for Arishta formulations is supported by India's extensive manufacturing capacity, which includes over 10,800 pharmaceutical manufacturing facilities. These facilities are equipped with advanced packaging and cold chain capabilities, ensuring the integrity and quality of pharmaceutical products during transit.

In recent years, Indian pharmaceutical companies have made substantial investments in infrastructure that meets global regulatory standards, enhancing their capacity to produce high-quality finished dosage forms. This commitment to quality is evidenced by the industry's strong compliance track record with international regulatory bodies, including the USFDA and WHO.

There are no significant reports of supply disruptions in the India-Bahrain pharmaceutical trade. Indian manufacturers continue to expand their capacities to meet growing global demand, ensuring a stable and reliable supply of Arishta formulations to Bahrain.

For Bahraini buyers sourcing Arishta formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Arishta formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts and storage capabilities. Indian manufacturers are generally flexible and can accommodate varying order sizes.

• Payment Terms: Standard payment terms in India-Bahrain pharmaceutical trade include letters of credit (LC) and telegraphic transfers (TT). Establish clear payment terms to maintain a smooth transaction process.

• Supplier Qualification Process: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities, verification of regulatory approvals (e.g., WHO-GMP, USFDA), and assessment of quality control systems.

• Regulatory Compliance: Ensure that the selected suppliers comply with Bahrain's regulatory requirements for pharmaceutical imports, including product registration and labeling standards.

By implementing these strategies, Bahraini buyers can establish a reliable and cost-effective supply chain for Arishta formulations from India.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming it meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for regulatory and tariff purposes.

3. Good Manufacturing Practice (GMP) Certificate: Issued by regulatory authorities, this certificate confirms the manufacturer complies with GMP standards.

4. Stability Data: Includes results from stability studies conducted under various environmental conditions, ensuring the product maintains its quality over time.

5. Batch Manufacturing Records (BMR): Detailed records of the production process for each batch, ensuring traceability and consistency.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and specifications of the product.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organization (CDSCO), indicating the product is approved for sale in the country of origin.

8. Insurance Certificates: Proof of product liability insurance, providing coverage in case of product-related issues.

By meticulously following these guidelines, Bahrain companies can ensure the selection of reliable Indian suppliers for Arishta formulations, thereby safeguarding product quality and regulatory compliance.